FDA Insight: Utilizing 3D Models to Drive Drug Development & Regulatory Acceptance

Time: 9:10 am
day: Day Two


  • Outlining the latest developments to incorporate 3D model data to support translational success
  • Addressing the evidence required to advance drug candidates from preclinical 3D studies into phase I clinical trials
  • The need to adapt guidelines, define context of use across the model continuum and using 3D systems to support in vivo evidence